| Literature DB >> 30744377 |
Joon Yoon1, Heebal Kim1,2.
Abstract
OBJECTIVE: Recent studies have implied that gene expression has high tissue-specificity, and therefore it is essential to investigate gene expression in a variety of tissues when performing the transcriptomic analysis. In addition, the gradual increase of long non-coding RNA (lncRNA) annotation database has increased the importance and proportion of mapped reads accordingly.Entities:
Keywords: Cattle; Expression Profile; Genic lncRNA; RNA-seq; Sexually Dimorphic; Tissue Specificity
Year: 2018 PMID: 30744377 PMCID: PMC6603329 DOI: 10.5713/ajas.18.0516
Source DB: PubMed Journal: Asian-Australas J Anim Sci ISSN: 1011-2367 Impact factor: 2.509
The number of detected DEGs in the two protocols
| Type | Muscle | Adipose tissue | Pituitary gland | Liver |
|---|---|---|---|---|
| Intersect | 17 | 3 | 33 | 23 |
| mRNA only | 20 | 20 | 7 | 8 |
| mRNA and lncRNA | 21 | 20 | 7 | 8 |
lncRNA, long non-coding RNA; DEGs, differentially expressed genes.
The three types in the table are intersection DEG between the two pipelines and each pipeline-specific DEGs.
Figure 1FC-FC plot of 4 tissues. The fold-change in the mRNA pipeline is in the x-axis and fold-change in the suggested pipeline is in the y-axis. The plot displays the difference in fold-changes between the same BAM files under different quantification pipeline. The intersecting genes (circle), and pipeline-specific genes (squares and triangles) are respectively shaped.
Summary of GO terms for both pipelines in their respective tissues
| Tissue | Pipeline | Term | Count | p-value | Fold enrichment |
|---|---|---|---|---|---|
| P. Gland | mRNA | GO:0016998~cell wall macromolecule catabolic process | 5 | ||
| P. Gland | mRNA | GO:0050829~defense response to Gram-negative bacterium | 5 | ||
| P. Gland | mRNA | GO:0019835~cytolysis | 4 | ||
| P. Gland | mRNA | GO:0050830~defense response to Gram-positive bacterium | 5 | ||
| P. Gland | mRNA | GO:0007417~central nervous system development | 3 | ||
| P. Gland | mRNA | GO:0007155~cell adhesion | 4 | ||
| P. Gland | mRNA | GO:0007586~digestion | 2 | ||
| P. Gland | mRNA | 2 | 0.058868 | 32 | |
| P. Gland | mRNA | GO:0021766~hippocampus development | 2 | ||
| P. Gland | mRNA | GO:0005615~extracellular space | |||
| P. Gland | mRNA | GO:0005578~proteinaceous extracellular matrix | 4 | ||
| P. Gland | mRNA | GO:0003796~lysozyme activity | 6 | ||
| P. Gland | mRNA | GO:0005540~hyaluronic acid binding | 2 | ||
| P. Gland | mRNA | GO:0005201~extracellular matrix structural constituent | 2 | ||
| Adipose | mRNA | 2 | 0.029846 | 59.52273 | |
| Muscle | mRNA | 2 | 0.048822 | 36.42688 | |
| P. Gland | mRNA+lncRNA | GO:0016998~cell wall macromolecule catabolic process | 5 | 2.79E-08 | 144 |
| P. Gland | mRNA+lncRNA | GO:0050829~defense response to Gram-negative bacterium | 5 | 1.22E-06 | 59.07692 |
| P. Gland | mRNA+lncRNA | GO:0019835~cytolysis | 4 | 7.86E-06 | 97.01053 |
| P. Gland | mRNA+lncRNA | GO:0050830~defense response to Gram-positive bacterium | 5 | 8.01E-06 | 37.16129 |
| P. Gland | mRNA+lncRNA | GO:0007417~central nervous system development | 3 | 0.004154 | 30.05217 |
| P. Gland | mRNA+lncRNA | GO:0007155~cell adhesion | 4 | 0.005542 | 10.65434 |
| P. Gland | mRNA+lncRNA | GO:0007586~digestion | 2 | 0.053183 | 35.44615 |
| P. Gland | mRNA+lncRNA | GO:0021766~hippocampus development | 2 | 0.067028 | 27.92727 |
| P. Gland | mRNA+lncRNA | GO:0005615~extracellular space | 12 | 1.21E-06 | 6.103026 |
| P. Gland | mRNA+lncRNA | GO:0005578~proteinaceous extracellular matrix | 4 | 0.005405 | 10.79679 |
| P. Gland | mRNA+lncRNA | GO:0003796~lysozyme activity | 6 | 2.25E-10 | 154.0588 |
| P. Gland | mRNA+lncRNA | 2 | 0.037011 | 51.35294 | |
| P. Gland | mRNA+lncRNA | GO:0005540~hyaluronic acid binding | 2 | 0.045525 | 41.57143 |
| P. Gland | mRNA+lncRNA | GO:0005201~extracellular matrix structural constituent | 2 | 0.07886 | 23.59459 |
| Adipose | mRNA+lncRNA | 6 | 0.020001 | 2.983789 | |
| Muscle | mRNA+lncRNA | 2 | 0.059757 | 31.27602 | |
| Muscle | mRNA+lncRNA | 2 | 0.080017 | 23.11706 |
GO, gene ontology; lncRNA, long non-coding RNA.
The two pipelines are separated by a double-line break. The pipeline specific terms and their specific values are bolded if there are differences between the two pipelines’ result.
Summary of KEGG pathways for both pipelines in their respective tissues
| Tissue | Pipeline | Term | Count | p-value | Fold enrichment |
|---|---|---|---|---|---|
| P. Gland | Mrna | bta04970:Salivary secretion | 3 | ||
| P. Gland | mRNA | 2 | 0.059304 | 30.09127 | |
| Liver | mRNA | bta00140:Steroid hormone biosynthesis | |||
| Liver | mRNA | 2 | 0.072718 | 24.1882 | |
| Liver | mRNA | 2 | 0.08862 | 19.6961 | |
| Muscle | mRNA | 2 | 0.049696 | 31.59583 | |
| P. Gland | mRNA+lncRNA | bta04970:Salivary secretion | 3 | ||
| Liver | mRNA+lncRNA | bta00140:Steroid hormone biosynthesis |
KEGG, Kyoto encyclopedia of genes and genomes; lncRNA, long non-coding RNA.
The two pipelines are separated by a double-line break. The pipeline specific terms and their specific values are bolded if there are differences between the two pipelines’ result.
Figure 2David GO plot of rank and significance in the pituitary gland. Summarized GO terms are illustrated as points with different size for gene count and color for the ratio of gene over total input gene. The corresponding values can be found in (Table 2). The terms are ranked with their corresponding p-values. mRNA-only pipeline on the left and mRNA+lncRNA pipeline on the right. The mRNA-only pipeline-specific term is bolded and boxed, while the mRNA+lncRNA pipeline-specific term is bolded and underlined. GO, gene ontology; lncRNA, long non-coding RNA.
Figure 3FC-FC plot of adipose tissue. The FC-FC plot of fat indicates that the fat has the least number of intersecting genes (circle with black border), and most pipeline-specific genes (squares and triangles). Adipose tissue is the most susceptible to the addition of lncRNA annotation.